FRACTYL HEALTH INC. - COMMON STOCK

Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions

23 6 2024 13:30:00 提供 Nasdaq GlobeNewswire

Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions

29 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024

20 5 2024 06:00:00 提供 Nasdaq GlobeNewswire

Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates

13 5 2024 16:00:00 提供 Nasdaq GlobeNewswire

Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)

13 5 2024 06:00:00 提供 Nasdaq GlobeNewswire

Fractyl Health to Present at BofA Securities 2024 Health Care Conference

08 5 2024 06:00:00 提供 Nasdaq GlobeNewswire

Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024

07 5 2024 06:00:00 提供 Nasdaq GlobeNewswire

Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting

30 4 2024 08:38:00 提供 Nasdaq GlobeNewswire

Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

02 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

01 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

01 4 2024 06:00:00 提供 Nasdaq GlobeNewswire

UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

12 3 2024 14:06:28 提供 Nasdaq GlobeNewswire

Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

12 3 2024 08:38:26 提供 Nasdaq GlobeNewswire

Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

20 2 2024 08:38:00 提供 Nasdaq GlobeNewswire